Noleus Technologies is a technology company.
Noleus Technologies has raised $30K across 1 funding round.
Noleus Technologies has raised $30K in total across 1 funding round.
Noleus Technologies is a medical device company founded in 2015 and headquartered in Sugar Land, Texas, specializing in technologies to reduce swelling and accelerate recovery after abdominal surgery[1][2][3]. Its flagship disposable device targets post-operative ileus—a lack of intestinal movement—by mitigating intestinal wall swelling, aiming to shorten hospital stays and establish a new standard of care in the $5.8B total addressable market for this unmet need[1][2][3]. The company has raised $3.11M in total funding, with its last round of $2.2M three years ago, and remains in the prototype-ready to debt stage while pursuing FDA clearance and an exit to a major medical device manufacturer[1][2].
Noleus Technologies was founded in December 2015 by Swarna Balasubramaniam, MD, a board-certified colon and rectal surgeon with over 20 years of experience, trained at the Mayo Clinic and University of Southern California[1][2][3]. The idea emerged 12 years earlier when Balasubramaniam, observing post-surgical swelling via CT scans likened to swollen fingers, sketched a device concept but initially shelved it despite physician and engineer feedback[1]. A sales rep later presented a similar device, reigniting her vision for "Noleus" (no ileus), leading her to launch the company with a biomedical engineer co-founder experienced in Class III device trials[1][2]. Early traction included accelerator programs like HealthWildcatters, TMCx7, MassChallenge Houston (Gold Prize winner), StartX Med, and Walleye Tank grand prize at Mayo Rochester[3].
Noleus rides the wave of precision medtech for surgical recovery, where post-op complications like ileus drive $5.8B in costs amid rising abdominal procedures fueled by aging populations and minimally invasive techniques[2]. Timing aligns with advanced imaging (e.g., CT) enabling swelling visualization and FDA pathways for Class III devices, amplified by accelerators like StartX and MassChallenge that bridge Texas' biotech hubs to national ecosystems[3]. It influences healthcare by targeting immunology/inflammation in host-directed therapies, potentially reducing complications and hospital stays, while Texas' med device cluster (Houston/Sugar Land) provides tailwinds via networks like TMC Innovation and MTEC[3][5].
Noleus is primed for FDA clearance and commercialization, leveraging recent patents and founder visibility (e.g., MDG Boston talks) to secure partnerships or acquisition by giants like Medtronic[1][3]. Trends in value-based care and AI-enhanced imaging will boost demand for ileus solutions, evolving its influence from niche accelerator darling to standard-of-care player. Watch for funding spikes or trials, as low recent activity signals a pivot toward launch[5]—positioning this surgeon-led innovator to transform post-surgical norms, much like its origin from a rediscovered sketch to patented reality.
Noleus Technologies has raised $30K in total across 1 funding round.
Noleus Technologies's investors include Health Wildcatters.
Noleus Technologies has raised $30K across 1 funding round. Most recently, it raised $30K Seed in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $30K Seed | Health Wildcatters |